Divi's Laboratories Limited (DIVISLAB) — Board Meeting Announcement
Revenue: ₹7,595 CrNet Profit: ₹1,851 Cr
📢 Key Event
Board approved Q3 FY26 financial results with consolidated total income of ₹2,692 crores and ₹74 crores exceptional labour code impact.
🔮 What's Next
Company will continue monitoring finalisation of Central and State Rules and clarifications on Labour Codes; may provide updated impact on employee benefits liability when available.
💡 Investor Takeaway
Strong nine-month growth of 14.8% in total income offset by a one-time ₹74 crore labour code charge, with quarterly PAT decline driven by higher material costs and exceptional items despite revenue growth.
Divi's Laboratories reported consolidated total income of **₹2,692 crores** for Q3 FY26, up **12.1%** YoY from ₹2,401 crores. Profit before tax (after ₹74 crores labour code impact) reached **₹780 crores** versus ₹726 crores YoY. Profit after tax declined to **₹583 crores** from ₹589 crores YoY. For nine months ended December 31, 2025, consolidated total income stood at **₹8,081 crores**, up **14.8%** YoY from ₹7,041 crores, with PAT of **₹1,817 crores** versus ₹1,529 crores YoY.
📄 View Original Announcement (PDF)
About Divi's Laboratories Limited (DIVISLAB)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Market Cap: ₹1,79,470.03 Cr
P/E: 72.4
ROE: 16.6%
ROCE: 22.1%
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.